glp 1 agonists in development Another milestone the evolution of GLP-1-based diabetes therapies History of glucagon-like peptide-1 receptor

(HKEX: 1672) has unveiled ASC35, a next-generation GLP-1/GIP dual peptide agonist designed for once-monthly subcutaneous dosing in obesity treatment.

GoodRx reports that while satisfaction with GLP-1s for weight loss is high, costs and access issues significantly impact patient experiences.

Type 2 Diabetes Mellitus (T2DM) is one of the most common metabolic disorders worldwide

How GLP-1 and GIP pathways work, why dual-action tirzepatide (Mounjaro) differs from GLP-1-only medicines, and what trial averages mean for UK patients.

When used alongside healthy eating, regular movement, and mindful habits, these herbs can be part of a long-term, sustainable approach to weight management